Molbio Diagnostics - IPO Report

Molbio Diagnostics is a molecular diagnostics company focused on developing, manufacturing and commercialising point-of-care (POC) diagnostic solutions for infectious and non-communicable diseases. Its products enable rapid, accurate and cost-effective testing closer to patients, reducing dependence on centralised laboratories and improving access to healthcare.

The company's flagship Truenat platform is a portable, battery-operated PCR-based molecular diagnostic system that delivers results in about an hour. The platform comprises the Trueprep sample preparation device, Truelab analyzers (UnoDx, Duo and Quattro) and ready-to-use Truenat test kits, supporting diagnosis of over 30 diseases through 43 assays, including TB, COVID-19, HIV, Hepatitis B & C and HPV. Its Truenat TB test is among the few WHO-endorsed rapid molecular tests for tuberculosis detection and rifampicin resistance.

Molbio has built a global presence, with over 12,500 Truenat devices installed across more than 90 countries as of March 2026. The company has further diversified its healthcare offerings through subsidiaries Prognosys Medical Systems and OptraScan, while partnerships such as UE Lifesciences strengthen its capabilities in breast health diagnostics.

The company has built a strong R&D-led manufacturing platform, supported by 16 Indian and 191 international patents. It operates six manufacturing facilities across India with an annual installed capacity of 5,400 diagnostic devices and 3.9 crore test kits. Its globally certified manufacturing infrastructure provides scalability to support future growth.